Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Current Assets (2018 - 2026)

10x Genomics' Current Assets history spans 8 years, with the latest figure at $684.5 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 17.12% to $684.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $684.5 million, a 17.12% increase, with the full-year FY2025 number at $684.5 million, up 17.12% from a year prior.
  • Current Assets hit $684.5 million in Q4 2025 for 10x Genomics, up from $659.8 million in the prior quarter.
  • Over the last five years, Current Assets for TXG hit a ceiling of $757.2 million in Q2 2021 and a floor of $562.3 million in Q3 2023.
  • Historically, Current Assets has averaged $643.5 million across 5 years, with a median of $632.2 million in 2022.
  • The widest YoY moves for Current Assets: up 73.53% in 2021, down 17.36% in 2021.
  • Tracing TXG's Current Assets over 5 years: stood at $747.6 million in 2021, then dropped by 15.06% to $635.0 million in 2022, then fell by 6.14% to $596.0 million in 2023, then dropped by 1.95% to $584.4 million in 2024, then increased by 17.12% to $684.5 million in 2025.
  • Business Quant data shows Current Assets for TXG at $684.5 million in Q4 2025, $659.8 million in Q3 2025, and $655.7 million in Q2 2025.